Payment overview · 2025
General Payments
$1,171.33
48 reported records · 17 companies
Healthcare provider profile · identity verified
Jeffrey Thomas Johnston, MD
Allopathic & Osteopathic Physicians|Surgery|Vascular Surgery · MEMPHIS, TN · NPI 1679969729
Verified facts
What the public records show
CMS Open Payments records show Jeffrey Thomas Johnston, MD received $1,171.33 in general payments during 2025 across 48 reported records.
W. L. Gore & Associates, Inc. accounted for 32.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $378.03 | 32.3% | 12 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $154.56 | 13.2% | 7 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $99.90 | 8.5% | 4 | 2025 |
| AtriCure, Inc. | Unresolved — no canonical attribution shown | $79.45 | 6.8% | 2 | 2025 |
| Artivion, Inc. | Unresolved — no canonical attribution shown | $75.75 | 6.5% | 4 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $59.14 | 5.0% | 3 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $58.66 | 5.0% | 3 | 2025 |
| LeMaitre Vascular, Inc. | Unresolved — no canonical attribution shown | $39.49 | 3.4% | 2 | 2025 |
| Hydrofera LLC | Unresolved — no canonical attribution shown | $38.30 | 3.3% | 2 | 2025 |
| CORDIS US CORP. | Unresolved — no canonical attribution shown | $34.75 | 3.0% | 2 | 2025 |
| InspireMD Ltd | Unresolved — no canonical attribution shown | $32.34 | 2.8% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$24.59 | 2.1% | 1 | 2025 |
| Bolton Medical Inc | Unresolved — no canonical attribution shown | $23.76 | 2.0% | 1 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $21.86 | 1.9% | 1 | 2025 |
| ConvaTec Inc. | Unresolved — no canonical attribution shown | $18.61 | 1.6% | 1 | 2025 |
| Zimmer Biomet Holdings, Inc. | Unresolved — no canonical attribution shown | $17.26 | 1.5% | 1 | 2025 |
| Veryan Medical Incorporated | Unresolved — no canonical attribution shown | $14.88 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,171.33 | 48 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GORE VIABAHN VBX Balloon Expandable Endo Normalized: gore viabahn vbx balloon expandable endo |
Device | W. L. Gore & Associates, Inc. | $152.53 | 6 | 2025 |
Source payment records
|
|||||
| GORE TAG Conformable Thoracic Stent Graft Normalized: gore tag conformable thoracic stent graft |
Device | W. L. Gore & Associates, Inc. | $99.85 | 1 | 2025 |
Source payment records
|
|||||
| BIOGLUE SURGICAL ADHESIVE Normalized: bioglue surgical adhesive |
Device | Artivion, Inc. | $75.75 | 4 | 2025 |
Source payment records
|
|||||
| Vascular Normalized: vascular |
Device | Artivion, Inc. | $75.75 | 4 | 2025 |
Source payment records
|
|||||
| ENROUTE Transcarotid Neuroprotection System Normalized: enroute transcarotid neuroprotection system |
Device | Boston Scientific Corporation | $71.01 | 3 | 2025 |
Source payment records
|
|||||
| GORE EXCLUDER Iliac Branch Endoprosthesis Normalized: gore excluder iliac branch endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $65.22 | 2 | 2025 |
Source payment records
|
|||||
| STRAVIX Normalized: stravix |
Biological | Smith+Nephew, Inc. | $58.66 | 3 | 2025 |
Source payment records
|
|||||
| PHOTOFIX DECELLULARIZED BOVINE PERICARDIUM Normalized: photofix decellularized bovine pericardium |
Device | Artivion, Inc. | $58.23 | 3 | 2025 |
Source payment records
|
|||||
| ATRICURE CRYOICE CRYOSPHERE CRYOABLATION SYSTEM Normalized: atricure cryoice cryosphere cryoablation system |
Device | AtriCure, Inc. | $57.64 | 1 | 2025 |
Source payment records
|
|||||
| SYNERGY ABLATION SYSTEM Normalized: synergy ablation system |
Device | AtriCure, Inc. | $57.64 | 1 | 2025 |
Source payment records
|
|||||
| SIMPLIMAX Normalized: simplimax |
Medical Supply | Organogenesis Inc. | $47.94 | 2 | 2025 |
Source payment records
|
|||||
| VIA MATRIX Normalized: via matrix |
Medical Supply | Organogenesis Inc. | $47.01 | 2 | 2025 |
Source payment records
|
|||||
| Penumbra System Normalized: penumbra system |
Device | Penumbra, Inc. | $39.24 | 2 | 2025 |
Source payment records
|
|||||
| HYDROFERA BLUE Normalized: hydrofera blue |
Device | Hydrofera LLC | $38.30 | 2 | 2025 |
Source payment records
|
|||||
| APLIGRAF Normalized: apligraf |
Device | Organogenesis Inc. | $35.82 | 1 | 2025 |
Source payment records
|
|||||
| CGuard Prime Carotid Stent System Normalized: cguard prime carotid stent system |
Device | InspireMD Ltd | $32.34 | 1 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $28.89 | 1 | 2025 |
Source payment records
|
|||||
| MVP Normalized: mvp |
Device | Medtronic, Inc. | $24.59 | 1 | 2025 |
Source payment records
|
|||||
| THORAFLEX HYBRID Normalized: thoraflex hybrid |
Device | Bolton Medical Inc | $23.76 | 1 | 2025 |
Source payment records
|
|||||
| AFFINITY Normalized: affinity |
Medical Supply | Organogenesis Inc. | $22.07 | 1 | 2025 |
Source payment records
|
|||||
| GORE TAG Conformable Thoracic Endoprosthesis Normalized: gore tag conformable thoracic endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $22.04 | 1 | 2025 |
Source payment records
|
|||||
| AFX2 Bifurcated Endograft System Normalized: afx2 bifurcated endograft system |
Device | Endologix LLC | $21.86 | 1 | 2025 |
Source payment records
|
|||||
| Ovation iX Iliac Stent Graft Normalized: ovation ix iliac stent graft |
Device | Endologix LLC | $21.86 | 1 | 2025 |
Source payment records
|
|||||
| AtriCure cryoICE Cryoablation System (CRYO2) Normalized: atricure cryoice cryoablation system cryo2 |
Device | AtriCure, Inc. | $21.81 | 1 | 2025 |
Source payment records
|
|||||
| ARTEGRAFT VASCULAR GRAFT Normalized: artegraft vascular graft |
Device | LeMaitre Vascular, Inc. | $21.67 | 1 | 2025 |
Source payment records
|
|||||
| PRECISE PRO RX Normalized: precise pro rx |
Device | CORDIS US CORP. | $20.65 | 1 | 2025 |
Source payment records
|
|||||
| GORE VIABAHN Endoprosthesis with Heparin Normalized: gore viabahn endoprosthesis with heparin |
Device | W. L. Gore & Associates, Inc. | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| RUBY Coil Normalized: ruby coil |
Device | Penumbra, Inc. | $19.90 | 1 | 2025 |
Source payment records
|
|||||
| AQUACEL AG+ EXTRA Normalized: aquacel ag extra |
Device | ConvaTec Inc. | $18.61 | 1 | 2025 |
Source payment records
|
|||||
| GORE PROPATEN Vascular Graft Normalized: gore propaten vascular graft |
Device | W. L. Gore & Associates, Inc. | $18.41 | 1 | 2025 |
Source payment records
|
|||||
| HYDRO LEMAITRE VALVULOTOME Normalized: hydro lemaitre valvulotome |
Device | LeMaitre Vascular, Inc. | $17.82 | 1 | 2025 |
Source payment records
|
|||||
| STERNALOCK BLU SYSTEM Normalized: sternalock blu system |
Device | Zimmer Biomet Holdings, Inc. | $17.26 | 1 | 2025 |
Source payment records
|
|||||
| BioMimics 3D Vascular Stent System Normalized: biomimics 3d vascular stent system |
Device | Veryan Medical Incorporated | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| MYNX CONTROL VENOUS Normalized: mynx control venous |
Device | CORDIS US CORP. | $14.10 | 1 | 2025 |
Source payment records
|
|||||
| PURAPLY WOUND MATRIX Normalized: puraply wound matrix |
Device | Organogenesis Inc. | $1.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 34 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 12 | 12 |
| Cilostazol | Cilostazol | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,171.33 · 48 records | W. L. Gore & Associates, Inc. | AFFINITY, AFX2 Bifurcated Endograft System, APLIGRAF, AQUACEL AG+ EXTRA, ARTEGRAFT VASCULAR GRAFT, ATRICURE CRYOICE CRYOSPHERE CRYOABLATION SYSTEM, AtriCure cryoICE Cryoablation System (CRYO2), BIOGLUE SURGICAL ADHESIVE, BioMimics 3D Vascular Stent System, CGuard Prime Carotid Stent System, ENROUTE Transcarotid Neuroprotection System, GORE EXCLUDER Iliac Branch Endoprosthesis, GORE PROPATEN Vascular Graft, GORE TAG Conformable Thoracic Endoprosthesis, GORE TAG Conformable Thoracic Stent Graft, GORE VIABAHN Endoprosthesis with Heparin, GORE VIABAHN VBX Balloon Expandable Endo, General - Therapies, HYDRO LEMAITRE VALVULOTOME, HYDROFERA BLUE, MVP, MYNX CONTROL VENOUS, Ovation iX Iliac Stent Graft, PHOTOFIX DECELLULARIZED BOVINE PERICARDIUM, PRECISE PRO RX, PURAPLY WOUND MATRIX, Penumbra System, RUBY Coil, SIMPLIMAX, STERNALOCK BLU SYSTEM, STRAVIX, SYNERGY ABLATION SYSTEM, THORAFLEX HYBRID, VIA MATRIX, Vascular | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error